270 related articles for article (PubMed ID: 10667639)
1. Pharmacologic aspects of a phlebotropic drug in CVI-associated edema.
Ramelet AA
Angiology; 2000 Jan; 51(1):19-23. PubMed ID: 10667639
[TBL] [Abstract][Full Text] [Related]
2. Clinical efficacy of micronized purified flavonoid fraction (MPFF) in edema.
Olszewski W
Angiology; 2000 Jan; 51(1):25-9. PubMed ID: 10667640
[TBL] [Abstract][Full Text] [Related]
3. RELIEF study: first consolidated European data. Reflux assEssment and quaLity of lIfe improvement with micronized Flavonoids.
Jantet G
Angiology; 2000 Jan; 51(1):31-7. PubMed ID: 10667641
[TBL] [Abstract][Full Text] [Related]
4. Chronic venous insufficiency: worldwide results of the RELIEF study. Reflux assEssment and quaLity of lIfe improvEment with micronized Flavonoids.
Jantet G
Angiology; 2002; 53(3):245-56. PubMed ID: 12025911
[TBL] [Abstract][Full Text] [Related]
5. Micronised purified flavonoid fraction: a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids.
Lyseng-Williamson KA; Perry CM
Drugs; 2003; 63(1):71-100. PubMed ID: 12487623
[TBL] [Abstract][Full Text] [Related]
6. From symptoms to leg edema: efficacy of Daflon 500 mg.
Nicolaides AN
Angiology; 2003; 54 Suppl 1():S33-44. PubMed ID: 12934755
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy of micronized purified flavonoid fraction: an overview.
Struckmann JR
J Vasc Res; 1999; 36 Suppl 1():37-41. PubMed ID: 10474049
[TBL] [Abstract][Full Text] [Related]
8. Protective Effects of Micronized Purified Flavonoid Fraction (MPFF) on a Novel Experimental Model of Chronic Venous Hypertension.
das Graças C de Souza M; Cyrino FZ; de Carvalho JJ; Blanc-Guillemaud V; Bouskela E
Eur J Vasc Endovasc Surg; 2018 May; 55(5):694-702. PubMed ID: 29588131
[TBL] [Abstract][Full Text] [Related]
9. Recommendations for the medical management of chronic venous disease: The role of Micronized Purified Flavanoid Fraction (MPFF).
Bush R; Comerota A; Meissner M; Raffetto JD; Hahn SR; Freeman K
Phlebology; 2017 Apr; 32(1_suppl):3-19. PubMed ID: 28211296
[TBL] [Abstract][Full Text] [Related]
10. [Therapeutic potential of micronized purified flavonoid fraction (MPFF) of diosmin and hesperidin in treatment chronic venous disorder].
Hnátek L
Vnitr Lek; 2015 Sep; 61(9):807-14. PubMed ID: 26465280
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of micronized purified flavonoid fraction (Daflon®) on improving individual symptoms, signs and quality of life in patients with chronic venous disease: a systematic review and meta-analysis of randomized double-blind placebo-controlled trials.
Kakkos SK; Nicolaides AN
Int Angiol; 2018 Apr; 37(2):143-154. PubMed ID: 29385792
[TBL] [Abstract][Full Text] [Related]
12. Clinical benefits of Daflon 500 mg in the most severe stages of chronic venous insufficiency.
Ramelet AA
Angiology; 2001 Aug; 52 Suppl 1():S49-56. PubMed ID: 11510597
[TBL] [Abstract][Full Text] [Related]
13. Micronized purified flavonoid fraction and the treatment of chronic venous insufficiency: microcirculatory mechanisms.
Smith PD
Microcirculation; 2000; 7(6 Pt 2):S35-40. PubMed ID: 11151970
[TBL] [Abstract][Full Text] [Related]
14. Micronized Purified Flavonoid Fraction (MPFF) for Patients Suffering from Chronic Venous Disease: A Review of New Evidence.
Ulloa JH
Adv Ther; 2019 Mar; 36(Suppl 1):20-25. PubMed ID: 30758743
[TBL] [Abstract][Full Text] [Related]
15. [Edema as a measure for severity of chronic venous insufficiency and efficacy of its treatment].
Sapelkin SV
Angiol Sosud Khir; 2008; 14(3):79-81. PubMed ID: 19791434
[TBL] [Abstract][Full Text] [Related]
16. Implications of the lymphatic system in CVI-associated edema.
Mortimer PS
Angiology; 2000 Jan; 51(1):3-7. PubMed ID: 10667636
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic approach to chronic venous insufficiency and its complications: place of Daflon 500 mg.
Bergan JJ; Schmid-Schönbein GW; Takase S
Angiology; 2001 Aug; 52 Suppl 1():S43-7. PubMed ID: 11510596
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms in experimental venous valve failure and their modification by Daflon 500 mg.
Pascarella L; Lulic D; Penn AH; Alsaigh T; Lee J; Shin H; Kapur V; Bergan JJ; Schmid-Schönbein GW
Eur J Vasc Endovasc Surg; 2008 Jan; 35(1):102-10. PubMed ID: 17890112
[TBL] [Abstract][Full Text] [Related]
19. Different flavonoids present in the micronized purified flavonoid fraction (Daflon 500 mg) contribute to its anti-hyperpermeability effect in the hamster cheek pouch microcirculation.
Paysant J; Sansilvestri-Morel P; Bouskela E; Verbeuren TJ
Int Angiol; 2008 Feb; 27(1):81-5. PubMed ID: 18277344
[TBL] [Abstract][Full Text] [Related]
20. From skin disorders to venous leg ulcers: pathophysiology and efficacy of Daflon 500 mg in ulcer healing.
Coleridge Smith PD
Angiology; 2003; 54 Suppl 1():S45-50. PubMed ID: 12934756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
